Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Retension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continues

20 September 2026 · By · Wire by Fusion42

Published

20 September 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at pharma.economictimes.indiatimes.com →

◆ Verified

Fusion42 · 20 September 2026 · Fusion42 review

Retension Pharmaceuticals and TRex Bio have filed for US IPOs, joining a series of biotech listings supported by acquisitions from major drugmakers and signalling strength in biotech despite broader market uncertainties.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 18 Sep 2026 and 20 Sep 2026.

◆ ◆ The Wire takeaway

The biotech IPO market in the US remains open despite market shocks, and you should view upcoming biotech listings as a chance to engage investors pivoting from acquisition to new offerings.

◆ Coverage

3 sources · first reported 18 Sep 2026 · latest 20 Sep 2026

◆ Related on Wire

◆ Topics

Biotechbiotechipodrugmakersus-marketcapital-raising